Lapatinib-d4

• CAT Number: S000494
• CAS Number: 1184263-99-7
• Molecular Formula: C29H22D4ClFN4O4S
• Molecular Weight: 585.08
• Purity: ≥95%
• IUPAC Name: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[(1,1,2,2-tetradeuterio-2-methylsulfonylethyl)amino]methyl]furan-2-yl]quinazolin-4-amine
• InChI: InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)/i11D2,12D2
• InChIKey: BCFGMOOMADDAQU-AREBVXNXSA-N
• SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

Lapatinib-d4（Cat No.:S000494） is a deuterated form of lapatinib, where four hydrogen atoms are replaced with deuterium. Lapatinib is a targeted therapy drug used primarily in the treatment of breast cancer, particularly HER2-positive breast cancers. It functions as a dual tyrosine kinase inhibitor, blocking both HER2 and EGFR pathways, which are involved in cell growth and proliferation. The introduction of deuterium in Lapatinib-d4 increases the drug’s metabolic stability, enabling more detailed and accurate pharmacokinetic studies.